EZH2 and systemic lupus erythematosus: Considering EZH2’s regulatory functions in T-cell and B-cell abnormalities of SLE patients (10, 16, 17, 51), we propose that EZH2 is a potent multivalent therapeutic target for SLE and warrants further clinical development.